Richter Fernanda Grace Bauk, Mattar André, Antonini Marcelo, Teixeira Marina Diógenes, Amorim Andressa Gonçalves, Millen Eduardo Camargo, Brenelli Fabricio Palermo, Cavalcante Francisco Pimentel, Zerwes Felipe, Frasson Antonio Luiz, Lopes Reginaldo Guedes Coelho, Gebrim Luiz Henrique, Real Juliana Monte
Hospital do Pérola Byington, São Paulo, Brazil.
Hospital da Mulher, Av Rio Branco 1080, São Paulo, 01206-001, Brazil.
Sci Rep. 2025 Feb 20;15(1):6174. doi: 10.1038/s41598-025-89841-0.
Body mass index (BMI) is a key factor in the progression of breast cancer (BC), with conflicting evidence on its influence on pathological complete response (pCR) following neoadjuvant chemotherapy (NAC). Despite these global findings, studies focusing on real-world Brazilian data remain scarce. This study aimed to evaluate the impact of BMI on pCR rates, recurrence-free survival (RFS), and overall survival (OS) in Brazilian women with BC treated with NAC. A retrospective cohort of 1,751 patients with stage I-III invasive primary BC treated between January 2011 and December 2020 at two public healthcare centers Hospital Pérola Byington (HPB) and Hospital do Servidor Público Estadual (HSPE) in Brazil was analyzed. Data included BMI categories (normal, overweight, and obese) and their associations with pCR, RFS, and OS outcomes. Obesity was prevalent (35.5%) among the cohort, with most patients being postmenopausal (50.9%). Tumors were predominantly stage III invasive ductal carcinoma, with triple-negative and luminal B subtypes being the most common. Radical surgery was performed in 79.8% of cases, achieving a pCR rate of 22.3%, and 30.9% of patients experienced recurrence, predominantly systemic (27.7%). No significant differences in pCR, RFS, or OS were observed across BMI categories. BMI was not associated with pCR, RFS, or OS in this large Brazilian cohort, highlighting the need for further studies to explore BMI dynamics during treatment and its potential influence on therapeutic outcomes. Future investigations in diverse healthcare settings may provide additional insights into optimizing breast cancer management across BMI strata.
体重指数（BMI）是乳腺癌（BC）进展的关键因素，关于其对新辅助化疗（NAC）后病理完全缓解（pCR）的影响，证据相互矛盾。尽管有这些全球范围内的研究结果，但针对巴西真实数据的研究仍然很少。本研究旨在评估BMI对接受NAC治疗的巴西BC女性患者的pCR率、无复发生存期（RFS）和总生存期（OS）的影响。对2011年1月至2020年12月期间在巴西两家公共医疗中心——佩罗拉·拜因顿医院（HPB）和圣保罗州立公务员医院（HSPE）接受治疗的1751例I-III期浸润性原发性BC患者进行了回顾性队列分析。数据包括BMI类别（正常、超重和肥胖）及其与pCR、RFS和OS结果的关联。该队列中肥胖较为普遍（35.5%），大多数患者为绝经后（50.9%）。肿瘤主要为III期浸润性导管癌，三阴性和管腔B亚型最为常见。79.8%的病例进行了根治性手术，pCR率为22.3%，30.9%的患者出现复发，主要为全身性复发（27.7%）。不同BMI类别在pCR、RFS或OS方面未观察到显著差异。在这个大型巴西队列中，BMI与pCR、RFS或OS均无关联，这突出表明需要进一步研究来探索治疗期间的BMI动态及其对治疗结果的潜在影响。未来在不同医疗环境中的研究可能会为优化不同BMI分层的乳腺癌管理提供更多见解。
